title: Cytogenetics in pediatric low-grade astrocytomas.
abstract: BACKGROUND
  Cytogenetic analysis in certain tumors is a vital part of classification and assignment of prognosis. Few studies have examined the value of cytogenetic analysis in pediatric brain tumors. This is especially true of low-grade astrocytomas (LGA) of childhood. This study examines the correlation between cytogenetic abnormalities and survival in children with low-grade astrocytomas. The literature on adults with LGA suggest better survival for those whose tumors have normal cytogenetics compared to those with abnormal. We hypothesized this would also be true of children with low-grade astrocytomas.
  
  
  METHODS
  A retrospective study was performed of children presenting between 1980 and 1998 to The Children's Hospital, Denver, who had LGA and on whose tumors informative cytogenetics had obtained.
  
  
  RESULTS
  One hundred and forty-nine children were diagnosed with histologically proven LGA. Twenty-nine had successful cytogenetic analysis. One or more chromosomal abnormalities were observed in eight tumors while normal karyotypes were observed in 21 tumors. Actuarial progression-free survival at 5 years was 87.5% for the eight children with abnormal cytogenetics and 43% for those with normal (P=0.56). Overall survival at 5 years was 83% for those with abnormal cytogenetics and 78% for those with normal (P=0.8). The differences in progression-free survival and overall survival between these two groups were not significant. Those children with WHO Grade I tumors had significantly superior progression-free and overall survival than those with Grade II tumors.
  
  
  CONCLUSIONS
  It appears unlikely that, for children with LGA, those with normal cytogenetics have a better prognosis than those with abnormal. Histologic grade is a better predictor of outcome than cytogenetics.
authors.affiliation: University of Colorado Health Sciences Center, Denver, Colorado, USA.
authors.forename: Lesley C
authors.initials: LC
authors.lastname: Orr
authors.forename: Julie
authors.initials: J
authors.lastname: Fleitz
authors.forename: Loris
authors.initials: L
authors.lastname: McGavran
authors.forename: Josephine
authors.initials: J
authors.lastname: Wyatt-Ashmead
authors.forename: Michael
authors.initials: M
authors.lastname: Handler
authors.forename: Nicholas K
authors.initials: NK
authors.lastname: Foreman
mesh_terms: D000293:Adolescent; D001254:Astrocytoma / Q000235:genetics* / Q000401:mortality; D016543:Central Nervous System Neoplasms / Q000235:genetics* / Q000401:mortality; D002648:Child; D002675:Child, Preschool; D002869:Chromosome Aberrations; D003120:Colorado / Q000453:epidemiology; D018572:Disease-Free Survival; D005260:Female; D005819:Genetic Markers; D006801:Humans; D007223:Infant; D008297:Male; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D005819:Genetic Markers